.jpg?format=webp&width=780)
In a study, Nivolumab significantly improved the objective response rate in treatment-naive renal cell carcinoma patients with or without Ipilimumab boosts. While results showed lower overall efficacy than upfront Nivolumab plus Ipilimumab, it remains a potential rescue strategy for second-line treatment. The study enrolled 207 patients and noted manageable side effects. This research offers hope for those with intermediate-risk or poor-risk clear-cell metastatic renal cell carcinoma, showing the potential of immunotherapeutic approaches in cancer treatment.
Like
Save
Share